abrdn plc Makes New Investment in Takeda Pharmaceutical Company Limited (NYSE:TAK)

abrdn plc purchased a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 105,073 shares of the company's stock, valued at approximately $1,499,000.

Other large investors have also made changes to their positions in the company. Hexagon Capital Partners LLC grew its stake in shares of Takeda Pharmaceutical by 65.7% during the 3rd quarter. Hexagon Capital Partners LLC now owns 5,548 shares of the company's stock valued at $86,000 after purchasing an additional 2,199 shares during the period. Blue Trust Inc. grew its stake in shares of Takeda Pharmaceutical by 91.1% during the 4th quarter. Blue Trust Inc. now owns 5,837 shares of the company's stock valued at $91,000 after acquiring an additional 2,782 shares during the period. Allworth Financial LP grew its stake in shares of Takeda Pharmaceutical by 111.2% during the 3rd quarter. Allworth Financial LP now owns 6,183 shares of the company's stock valued at $96,000 after acquiring an additional 3,256 shares during the period. New York State Common Retirement Fund bought a new position in shares of Takeda Pharmaceutical during the 3rd quarter valued at approximately $145,000. Finally, Bruce G. Allen Investments LLC bought a new position in shares of Takeda Pharmaceutical during the 4th quarter valued at approximately $138,000. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Stock Performance

Shares of NYSE:TAK traded down $0.08 during mid-day trading on Tuesday, reaching $13.09. 909,524 shares of the company traded hands, compared to its average volume of 1,805,891. The company's 50 day moving average price is $13.99 and its 200-day moving average price is $14.15. The firm has a market cap of $41.41 billion, a PE ratio of 19.83, a PEG ratio of 2.97 and a beta of 0.53. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.06 and a quick ratio of 0.55. Takeda Pharmaceutical Company Limited has a 52 week low of $13.01 and a 52 week high of $17.11.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.51 earnings per share (EPS) for the quarter. The company had revenue of $7.52 billion during the quarter. Takeda Pharmaceutical had a return on equity of 12.57% and a net margin of 6.90%. On average, equities analysts expect that Takeda Pharmaceutical Company Limited will post 1.5 EPS for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.